185 related articles for article (PubMed ID: 15134220)
1. Sphingolipid metabolism enzymes as targets for anticancer therapy.
Kok JW; Sietsma H
Curr Drug Targets; 2004 May; 5(4):375-82. PubMed ID: 15134220
[TBL] [Abstract][Full Text] [Related]
2. The involvement of sphingolipids in multidrug resistance.
Sietsma H; Veldman RJ; Kok JW
J Membr Biol; 2001 Jun; 181(3):153-62. PubMed ID: 11420602
[TBL] [Abstract][Full Text] [Related]
3. The Onus of Sphingolipid Enzymes in Cancer Drug Resistance.
Morad SAF; Cabot MC
Adv Cancer Res; 2018; 140():235-263. PubMed ID: 30060811
[TBL] [Abstract][Full Text] [Related]
4. The unfolding role of ceramide in coordinating retinoid-based cancer therapy.
Ghandour B; Dbaibo G; Darwiche N
Biochem J; 2021 Oct; 478(19):3621-3642. PubMed ID: 34648006
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
Kartal Yandım M; Apohan E; Baran Y
Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
[TBL] [Abstract][Full Text] [Related]
6. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
[TBL] [Abstract][Full Text] [Related]
8. Sphingolipid targets in cancer therapy.
Modrak DE; Gold DV; Goldenberg DM
Mol Cancer Ther; 2006 Feb; 5(2):200-8. PubMed ID: 16505092
[TBL] [Abstract][Full Text] [Related]
9. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
Gatt S; Dagan A
Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
[TBL] [Abstract][Full Text] [Related]
10. Sphingolipids and response to chemotherapy.
Dimanche-Boitrel MT; Rebillard A
Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
[TBL] [Abstract][Full Text] [Related]
11. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus.
Veldman RJ; Klappe K; Hinrichs J; Hummel I; van der Schaaf G; Sietsma H; Kok JW
FASEB J; 2002 Jul; 16(9):1111-3. PubMed ID: 12039850
[TBL] [Abstract][Full Text] [Related]
12. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
[TBL] [Abstract][Full Text] [Related]
13. Evolving concepts in cancer therapy through targeting sphingolipid metabolism.
Truman JP; García-Barros M; Obeid LM; Hannun YA
Biochim Biophys Acta; 2014 Aug; 1841(8):1174-88. PubMed ID: 24384461
[TBL] [Abstract][Full Text] [Related]
14. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come?
Radin NS
Eur J Biochem; 2001 Jan; 268(2):193-204. PubMed ID: 11168352
[TBL] [Abstract][Full Text] [Related]
15. Ceramide-based therapeutics for the treatment of cancer.
Barth BM; Cabot MC; Kester M
Anticancer Agents Med Chem; 2011 Nov; 11(9):911-9. PubMed ID: 21707481
[TBL] [Abstract][Full Text] [Related]
16. Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer.
Gomez-Larrauri A; Das Adhikari U; Aramburu-Nuñez M; Custodia A; Ouro A
Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357010
[TBL] [Abstract][Full Text] [Related]
17. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
18. Ceramide synthesis and metabolism as a target for cancer therapy.
Reynolds CP; Maurer BJ; Kolesnick RN
Cancer Lett; 2004 Apr; 206(2):169-80. PubMed ID: 15013522
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance.
Giussani P; Tringali C; Riboni L; Viani P; Venerando B
Int J Mol Sci; 2014 Mar; 15(3):4356-92. PubMed ID: 24625663
[TBL] [Abstract][Full Text] [Related]
20. Alteration of ceramide 1-O-functionalization as a promising approach for cancer therapy.
Ballereau S; Levade T; Genisson Y; Andrieu-Abadie N
Anticancer Agents Med Chem; 2012 May; 12(4):316-28. PubMed ID: 21554198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
